Aaron Ring
@aaronmring
Followers
9K
Following
19K
Media
179
Statuses
3K
Associate Professor at @FredHutch Studying #cytokines, (auto)antibodies, and #cancerimmunotherapy Founder: @SimchaTx, @Seranova, Stipple Bio, and @AriaxBio
Seattle, WA
Joined December 2017
T cells do the heavy lifting when it comes to the anti-tumor action of checkpoint immunotherapy. But do antibodies play a role too? That’s the question @yile_dai looked to answer in his thesis work, out today in @Nature! 🧵below https://t.co/VgTByRKRCX
21
111
404
Curious how to run BoltzGen? Our new tutorial walks through the complete workflow using our Adaptyv Nipah Competition submission as a real-world example. Target prep, hotspot selection, and launching parallel VHH/miniprotein campaigns. Full tutorial:
ariax.bio
Master the essentials of running BoltzGen for AI-powered binder design. This tutorial covers everything from target preparation to VHH and miniprotein campaigns using Ariax Bio's streamlined workflow.
1
17
94
Excited to share our new paper in Circulation: we engineered CAR T regulatory cells (CAR-Tregs) that target oxidized LDL and cut atherosclerotic plaque by ~70% in mice – a new way to tackle the most common form of heart disease. 🔗 Penn Medicine story:
3
10
28
With proprietary (Chai-2, JAM-2) and open-source (BoltzGen, Germinal, MBER, Protein Hunter) antibody design platforms emerging, the real question is what this actually means for drug development going forward. As I wrote in June, AI is for the underdogs! https://t.co/kOcSVssYLZ
ariax.bio
The question isn't whether AI will streamline drug discovery. It's what happens when the researchers with the wildest ideas—the ones pharma would never fund—can finally test them. AI democratizes who...
2
27
118
Open source strikes back! BoltzGen delivers Chai-2 level antibody design performance under an MIT license. Design nanobodies (VHH), cyclic-peptides, helicons, and miniproteins with an all-atom framework. Run it now without limits on Ariax. https://t.co/Z1wfWbToPt
ariax.bio
Announcing BoltzGen on Ariax: open-source, all-atom universal binder design for VHH antibodies, cyclic peptides, helicons, and more.
0
19
57
Genomic medicine has transformed lives through ex vivo cell therapies, now it’s time to make it scalable. Today we unveil Azalea Therapeutics, making in vivo genomic medicine a reality without compromising precision or specificity.
Jennifer Doudna's latest startup, Azalea Therapeutics, launched with $82M. It's based on virus like particles developed by CEO Jenny Hamilton and a new CAR-T trick developed by UCSF's Justin Eyquem. Azalea's goal? The ultimate in vivo CAR-T. @endpts -
1
10
72
Bindcraft workshop with @MartinPacesa using the best platform @AriaxBio in Mexico at @UNAM_MX campus Morelos
0
2
8
My takeaways: - For miniproteins/helicons against conventional protein targets, stick with BindCraft. It has better experimental success rates and runs faster. - For targets needing AA design, Boltzgen is a great option. - Boltzgen is the top open-source VHH platform right now.
2
5
65
Cons: - Experimental validation rates are inflated. Penguinpox/HA VHH binders are objective failures. Peptide binders called successes at 3.5-80 μM. - Pipeline is very computationally expensive. Took 72 GPU hours to get the recommended 10k designs for a 190 residue target.
2
3
54
BoltzGen seems pretty cool and we're putting it through its paces. Impressions so far: Pros: - Grateful for AA design across diverse modalities, esp. VHH. - VHH bind via CDRs (unlike side-binders w/MBER) and don't have excessive cys residues (like original Germinal designs).
2
8
120
Turbo mode has ruined me for regular BindCraft runs. It's like going from dial-up to DSL for protein design. There's no going back (take my word for this, GenZ).
Waiting days for BindCraft results? Not anymore. Turbo Mode splits your job across multiple GPUs for up to 8x faster completion. A typical 48-hour campaign now finishes in 6 hours:
0
2
38
We posted this preprint to @biorxiv_immuno that focuses on the idea that CD8 T cells can naturally survey and eliminate stem-cells in the colon epithelium that have neoantigens that are created by somatic mutation. This work was spearheaded by Jess Buck in the lab!
CD8 T cells mediate immunosurveillance for neoantigen+ epithelial stem cells in the colon https://t.co/10izGVNlt0
#biorxiv_immuno
4
24
117
Exciting to see our collaboration with @Google highlighted here — using AI to generate and test new biological hypotheses!
An exciting milestone for AI in science: Our C2S-Scale 27B foundation model, built with @Yale and based on Gemma, generated a novel hypothesis about cancer cellular behavior, which scientists experimentally validated in living cells. With more preclinical and clinical tests,
13
19
299
https://t.co/LsgdwXEmFt Let's focus on how to increase speed and reduce cost of developing medicines -- there are lessons we can learn here from Chinese biotechs. @ldtimmerman
@NeilUdassi
timmermanreport.com
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $199 per year, you reward quality independent biotech reporting,...
3
2
29
Preparing PDB files for protein design usually means wrestling with PyMOL or ChimeraX. We're making it easier. Watch us use our new Prep Inputs feature to go from PDB fetch → structure trimming → hotspot selection → launching a design job in a leisurely 75 seconds.
2
9
54
Meet the latest Nobel Prize winner with Bay Area ties … https://t.co/gOEXmNouEy
bizjournals.com
Fred Ramsdell, co-founder of Sonoma Biotherapeutics, shares Nobel Prize for discoveries in immune system regulation and autoimmune disease prevention.
2
5
16
Excited for the @CartographyBio team! IMO developing the most innovative T cell engager therapeutics pipeline for cancers with high unmet need. Looking forward to partnering with our new investors, @scienceman2023 @pfizer, @Amgen, @LGE_Global, and others, and very grateful for
We're excited to share the close of our $67M Series B financing, which will enable us to advance our lead program into the clinic & continued acceleration of additional oncology programs from our drug discovery platforms. Our CEO shares more below. Details: https://t.co/OyqGLYqQO2
0
7
38
Bravo @ManifoldBio for releasing MBER, entirely open source to boot! We'll be spinning this up. https://t.co/65sz01Z1LE
biorxiv.org
Recent machine learning approaches have achieved high success rates in designing protein binders that demonstrate in vitro binding to their targets. While open models for unconstrained “minibinder”...
2
17
116
Another banger piece from Brian on antibody design. If you want to start using protein design tools, I highly recommend following the Boolean Biotech blog.
New blogpost on the latest in AI antibody design. Including some code to easily run Germinal and IgGM on modal! https://t.co/G2ZC6fzUxq
0
0
11
Engineering synthetic agonists for targeted activation of Notch signaling @nchembio @MoffittNews @vcluca1 🇺🇸 https://t.co/4V060nBqyK
0
2
19
Go outside w a team Get exercise Give back A protocol for happiness :-) Thanks @ldtimmerman for bringing our community together throughout the year in such special ways Mount Katahdin, here we come! We're raising funds this time to support @DamonRunyon
2
2
23